Betulinic Acid Acts in Synergism with Imatinib Mesylate, Triggering Apoptosis in MDR Leukemia Cells

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disease, characterized by the presence of the oncogene BCR-ABL. Imatinib mesylate (IMA) is the first-line treatment for CML, and some treatment resistance has been reported. Natural products are rich sources of bioactive compounds with biological effects, opening a possibility to alter cell susceptibility to drugs such as imatinib. Herein, we evaluated the interference of betulinic acid and ursolic acid in glycoprotein P (P-gp) activity and the possible synergistic effect when associated with IMA by the Chou-Talalay method. Ursolic acid presented an IC₅₀ of 14.0 µM and 19.6 µM for K562 and Lucena 1, respectively, whilst betulinic acid presented an IC₅₀ of 8.6 µM and 12.5 µM for these cell lines. Evaluation of the combination of terpenoids and imatinib mesylate revealed that ursolic acid or betulinic acid acts in synergism with IMA, as indicated by the combination indexes (CI<1). Analysis of annexin V labeling demonstrated that a combination of IMA with betulinic acid enhances the inhibition on cell proliferation via the apoptosis pathway, with caspases 3/7 activation after 24 hours of treatment and inhibition of the STAT5/survivin pathway, decreasing cell viability. The combination of natural products and IMA on a multidrug-resistant leukemia cell line is a promising strategy for CML treatment.

Keywords

cancer - betulinic acid - ursolic acid - synergism - MDR

Publikationsverlauf

Eingereicht: 02. Mai 2024

Angenommen nach Revision: 12. Oktober 2024

Accepted Manuscript online:
12. Oktober 2024

Artikel online veröffentlicht:
12. November 2024

• References

• 1 Wang T, Cheng C, Peng L, Gao M, Xi M, Rousseaux S, Khochbin S, Wang J, Mi J. Combination of arsenic trioxide and Dasatinib: A new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med 2018; 22: 1614-1626
• 2 Kang ZJ, Liu YF, Xu LZ, Long ZJ, Huang D, Yang Y, Liu B, Feng JX, Pan YJ, Yan JS, Liu Q. The Philadelphia chromosome in leukemogenesis. Chin J Cancer 2016; 35: 48
• 3 Roskoski RJ. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 2015; 100: 1-23
• 4 Van Etten RA, Chan WW, Zaleskas VM, Evangelista P, Lazarides K, Peng C, Li S, Wise SC, Petillo P, Flynn DL. DCC-2036: A novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model. Blood 2007; 110: 463
• 5 Abdelhamed S, Yokoyama S, Hafiyani L, Kalauni SK, Hayakawa Y, Awale S, Saiki I. Identification of plant extracts sensitizing breast cancer cells to TRAIL. Oncol Rep 2013; 29: 1991-1998
• 6 Zhou J, Zhou T, Jiang M, Wang X, Liu Q, Zhan Z, Zhang X. Research progress on synergistic anti-tumor mechanisms of compounds in traditional Chinese medicine. J Tradit Chin Med 2014; 34: 100-105
• 7 Hussain A, Sharma C, Khan S, Shah K, Haque S. Aloe vera inhibits proliferation of human breast and cervical cancer cells and acts synergistically with cisplatin. Asian Pac J Cancer Prev 2015; 16: 2939-2946
• 8 Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446
• 9 Hu Q, Sun W, Wang C, Gu Z. Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv Drug Deliv Rev 2016; 98: 19-34
• 10 Moghaddam MG, Bin Ahmad FH, Samzadeh-Kermani A. Biological activity of betulinic acid: A review. Pharm Pharmacol 2012; 3: 119-123
• 11 Cimmino A, Andolfi A, Evidente A. Phytotoxic terpenes produced by phytopathogenic fungi and allelopathic plants. Nat Prod Commun 2014; 9: 401-408
• 12 Souza MT, Almeida JR, Araujo AA, Duarte MC, Gelain DP, Moreira JC, dos Santos MR, Quintans-Júnior LJ. Structure–activity relationship of terpenes with anti-inflammatory profile – A systematic review. Basic Clin Pharmacol Toxicol 2014; 115: 244-256
• 13 Zhang W, Men X, Lei P. Review on anti-tumor effect of triterpene acid compounds. J Cancer Res Ther 2014; 10: 14-19
• 14 Evidente A, Kornienko A, Lefranc F, Cimmino A, Dasari R, Evidente M, Mathieu V, Kiss R. Sesterterpenoids with anticancer activity. Curr Med Chem 2015; 22: 3502-3522
• 15 Sultana N. Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product. J Enzyme Inhib Med Chem 2011; 26: 616-642
• 16 Woźniak Ł, Skąpska S, Marszałek K. Ursolic acid–A pentacyclic triterpenoid with a wide spectrum of pharmacological activities. Molecules 2015; 20: 20614-20641
• 17 Cichewicz RH, Kouzi SA. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 2004; 24: 90-114
• 18 Zhang DM, Xu HG, Wang L, Li YJ, Sun PH, Wu XM, Wang GJ, Chen WM, Ye WC. Betulinic acid and its derivatives as potential antitumor agents. Med Res Rev 2015; 35: 1127-1155
• 19 Ali-Seyed M, Jantan I, Vijayaraghavan K, Bukhari SN. Betulinic acid: Recent advances in chemical modifications, effective delivery, and molecular mechanisms of a promising anticancer therapy. Chem Biol Drug Des 2016; 87: 517-536
• 20 Khwaza V, Oyedeji OO, Aderibigbe BA. Ursolic acid-based derivatives as potential anti-cancer agents: An update. Int J Mol Sci 2020; 21: 5920
• 21 Luo R, Fang D, Chu P, Wu H, Zhang Z, Tang Z. Multiple molecular targets in breast cancer therapy by betulinic acid. Biomed Pharmacother 2016; 84: 1321-1330
• 22 Shan JZ, Xuan YY, Ruan SQ, Sun M. Proliferation-inhibiting and apoptosis-inducing effects of ursolic acid and oleanolic acid on multi-drug resistance cancer cells in vitro. Chin J Integr Med 2011; 17: 607-611
• 23 Junco JJ, Mancha-Ramirez A, Malik G, Wei SJ, Kim DJ, Liang H, Slaga TJ. Ursolic acid and resveratrol synergize with chloroquine to reduce melanoma cell viability. Melanoma Res 2015; 25: 103-112
• 24 Shan J, Xuan Y, Zhang Q, Zhu C, Liu Z, Zhang S. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer. Protein Cell 2016; 7: 571-585
• 25 Aswathy M, Vijayan A, Daimary UD, Girisa S, Radhakrishnan KV, Kunnumakkara AB. Betulinic acid: A natural promising anticancer drug, current situation, and future perspectives. J Biochem Mol Toxicol 2022; 36: e23206
• 26 Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia 2005; 7: 162-170
• 27 Raghuvar Gopal DV, Narkar AA, Badrinath Y, Mishra KP, Joshi DS. Betulinic acid induces apoptosis in human chronic myelogenous leukemia (CML) cell line K-562 without altering the levels of Bcr-Abl. Toxicol Lett 2005; 155: 343-351
• 28 Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 2013; 13: 714-726
• 29 Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, Chan ZE, Yu M, Makheja M, Rayan NA, Lim MGL, Cheung AMS, Bari S, Chng WJ, Than H, Ouyang J, Rackham O, Tan TZ, Hwang WYK, Chuah C, Prabhakar S, Ong ST. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood 2023; 141: 2738-2755
• 30 Prado-Carrillo O, Arenas-Ramírez A, Llaguno-Munive M, Jurado R, Pérez-Rojas J, Cervera-Ceballos E, Garcia-Lopez P. Ketoconazole reverses imatinib resistance in human chronic myelogenous leukemia K562 cells. Int J Mol Sci 2022; 23: 7715
• 31 Wheatley SP, Altieri DC. Survivin at a glance. J Cell Sci 2019; 132: jcs223826
• 32 Jung SY, Kim C, Kim WS, Lee SG, Lee JH, Shim BS, Kim SH, Ahn KS, Ahn KS. Korean red ginseng extract enhances the anticancer effects of imatinib mesylate through abrogation p 38 and STAT5 activation in KBM-5 cells. Phytother Res 2015; 29: 1062-1072
• 33 Kim MB, Kim C, Chung WS, Cho JH, Nam D, Kim SH, Ahn KS. The hydrolysed products of iridoid glycosides can enhance imatinib mesylate-induced apoptosis in human myeloid leukaemia cells. Phytother Res 2015; 29: 434-443
• 34 Roskoski RJ. A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacol Res 2015; 100: 1-23
• 35 Roskoski RJ. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 2016; 103: 26-48
• 36 Vidal RS, Quarti J, Rodrigues MF, Rumjanek FD, Rumjanek VM. Metabolic reprogramming during multidrug resistance in leukemias. Front Oncol 2018; 8: 90
• 37 Daflon-Yunes N, Pinto-Silva FE, Vidal RS, Novis BF, Berguetti T, Lopes RR, Polycarpo C, Rumjanek VM. Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms. Mol Cell Biochem 2013; 383: 123-135
• 38 Rumjanek VM, Vidal RS, Maia RC. Multidrug resistance in chronic myeloid leukaemia: How much can we learn from MDR-CML cell lines?. Biosci Rep 2013; 33: e00081
• 39 Moselhy J, Srinivasan S, Ankem MK, Damodaran C. Natural products that target cancer stem cells. Anticancer Res 2015; 35: 5773-5788
• 40 Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P, Maroyi A, Dzobo K. Natural products for drug discovery in the 21st century: Innovations for novel drug discovery. Int J Mol Sci 2018; 19: 1578
• 41 Khurana RK, Jain A, Jain A, Sharma T, Singh B, Kesharwani P. Administration of antioxidants in cancer: Debate of the decade. Drug Discov Today 2018; 23: 763-770
• 42 Huang M, Lu JJ, Huang MQ, Bao JL, Chen XP, Wang YT. Terpenoids: natural products for cancer therapy. Expert Opin Investig Drugs 2012; 21: 1801-1818
• 43 Li Y, Xing D, Chen Q, Chen WR. Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NF-kappaB using ursolic acid. Int J Cancer 2010; 127: 462-473
• 44 Junco JJ, Mancha A, Malik G, Wei SJ, Kim DJ, Liang H, Slaga TJ. Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid. Mol Cancer Res 2013; 11: 1521-1529
• 45 Lin Z, Jiang J, Liu XS. Ursolic acid-mediated apoptosis of K562 cells involves Stat5/Akt pathway inhibition through the induction of Gfi-1. Sci Rep 2016; 6: 33358
• 46 Li Y, He K, Huang Y, Zheng D, Gao C, Cui L, Jin YH. Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog 2010; 49: 630-640
• 47 Ehrhardt H, Fulda S, Führer M, Debatin KM, Jeremias I. Betulinic acid-induced apoptosis in leukemia cells. Leukemia 2004; 18: 1406-1412
• 48 Wu Q, He J, Fang J, Hong M. Antitumor effect of betulinic acid on human acute leukemia K562 cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2010; 30: 453-457
• 49 Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446
• 50 Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681
• 51 Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 2009; 14: 885-890
• 52 Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, Wani MC, Wall ME, Hieken TJ, Das Gupta TK, Pezzuto JM. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1: 1046-1051
• 53 Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nuñez G, Krammer PH, Peter ME, Debatin KM. Betulinic acid triggers CD95 (APO-1/Fas)- and p 53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964
• 54 Fulda S, Jeremias I, Pietsch T, Debatin KM. Betulinic acid: A new chemotherapeutic agent in the treatment of neuroectodermal tumors. Klin Padiatr 1999; 211: 319-322
• 55 Bernardo PS, Lemos LGT, de Moraes GN, Maia RC. Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications. Blood Rev 2020; 43: 100671
• 56 Cong XL, Han ZC. Survivin and leukemia. Int J Hematol 2004; 80: 232-238
• 57 Maia RC, Wagner K, Cabral RH, Rumjanek VM. Heparin reverses Rhodamine 123 extrusion by multidrug resistant cells. Cancer Lett 1996; 106: 101-108
• 58 Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA. Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc 2001; 73: 57-69
• 59 Badisa RB, Darling-Reed SF, Joseph P, Cooperwood JS, Latinwo LM, Goodman CB. Selective cytotoxic activities of two novel synthetic drugs on human breast carcinoma MCF-7 cells. Anticancer Res 2009; 29: 2993-2996
• 60 Crawford L, Putnam D. Synthesis and characterization of macromolecular rhodamine tethers and their interactions with P-glycoprotein. Bioconjug Chem 2014; 25: 1462-1469